Skip to main content
NXTC
NASDAQ Life Sciences

NextCure Posts $6.8M Q3 Loss With $8.7M Cash Ahead of December 9 Merger Vote

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.78
Mkt Cap
$27.373M
52W Low
$1.55
52W High
$15.74
52W Position info
273% above low
Off High info
63% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NXTC has more than doubled off its 52-week low of $1.55.

Summary

NextCure reported a $6.8 million third-quarter net loss and $8.7 million of cash as of September 30, 2026, with the Avere merger — backed by roughly $820 million of committed financing — set for a December 9 stockholder vote now that the S-4 is effective.


Key Events · Earnings and Guidance · NXTC

  • Q3 Loss Narrows to $6.8M

    Net loss was $6.8 million for the three months ended September 30, 2026 versus $8.6 million a year earlier, helped by R&D falling to $4.5 million from $6.1 million after restructuring.

  • Cash Falls to $8.7M

    Cash, cash equivalents and marketable securities were $8.7 million at September 30, 2026, down $33.1 million from $41.8 million at December 31, 2025, driven by $35.2 million of operating cash use.

  • Merger Financing at ~$820M

    Commitments supporting the Avere merger total approximately $820 million: the previously announced $320 million concurrent private placement plus an additional $500 million placement, of which about $266 million is satisfied by cancelling Avere convertible notes.

  • December 9 Vote Is the Gate

    The S-4 was declared effective November 6, 2026, the record date was November 3, 2026, and the special stockholder meeting is set for December 9, 2026 at 9:00 a.m. Eastern; the Delaware Court of Chancery validated the July 2025 reverse split on November 2, 2026.


Analysis · NXTC · Life Sciences

The headline numbers are the point: NextCure ended September with $8.7 million of cash and securities, down from $41.8 million at year-end 2025 after burning $35.2 million over nine months. That is not a runway that funds a standalone company — it makes the December 9, 2026 stockholder vote on the Avere reverse merger close to existential, since the roughly $820 million of committed financing only arrives if the deal closes. The quarter itself was cleaner than a year ago (net loss $6.8 million vs $8.6 million, R&D down to $4.5 million on restructuring), but G&A rose to $4.4 million largely on $1.8 million of merger legal and professional fees. Two procedural hurdles are now cleared: the Delaware Court of Chancery validated the July 2025 reverse split on November 2, and the SEC declared the S-4 effective on November 6, so the proxy is out and the vote is the remaining gate.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NXTC was trading at $5.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXTC - Latest Insights

NXTC
Nov 10, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $5.43 info
Change: -$0.355 (-6%) info
Market Cap: $24.832M info
NXTC
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $5.43 info
Change: -$0.355 (-6%) info
Market Cap: $24.832M info
NXTC
Oct 30, 2026, 8:39 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $6.31
Real-time Price: $5.43 info
Change: -$0.885 (-14%) info
Market Cap: $24.832M info
NXTC
Sep 30, 2026, 7:36 PM EDT
Filing Type: S-4/A
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $5.43 info
Change: +$0.415 (+8%) info
Market Cap: $24.832M info
NXTC
Sep 25, 2026, 4:12 PM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $5.08
Real-time Price: $5.43 info
Change: +$0.345 (+7%) info
Market Cap: $24.832M info